Sign in →

Test Code APBTS Adaptor Protein 3 Beta2 (AP3B2) Antibody, Tissue Immunofluorescence Titer, Serum


Specimen Required


Only orderable as a reflex. For more information see:

-AIAES / Axonal Neuropathy, Autoimmune/Paraneoplastic Evaluation, Serum

-DYS2 / Dysautonomia, Autoimmune/Paraneoplastic Evaluation, Serum

-GID2 / Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum

-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum


Useful For

The differential diagnosis of patients presenting with mixed cerebellar and sensory ataxia and myeloneuropathy

 

Reporting an end titer result from serum specimens

Method Name

Only orderable as a reflex. For more information see:

-AIAES / Axonal Neuropathy, Autoimmune/Paraneoplastic Evaluation, Serum

-DYS2 / Dysautonomia, Autoimmune/Paraneoplastic Evaluation, Serum

-GID2 / Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum

-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum

 

Indirect Immunofluorescence Assay (IFA)

Reporting Name

AP3B2 IFA Titer, S

Specimen Type

Serum

Specimen Minimum Volume

See Specimen Required

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Clinical Information

AP3B2 (adaptor protein 3 beta2)-IgG is a marker of an autoimmune disorder unified by gait instability as the predominant neurologic presentation. Patients present with either cerebellar, dorsal column, or sensory neuronal dysfunction. Clinical improvement following treatment has been reported. AP3B2 autoimmunity appears rare, is accompanied by ataxia (sensory or cerebellar), and is potentially treatable.

Reference Values

Only orderable as a reflex. For more information see:

-AIAES / Axonal Neuropathy, Autoimmune/Paraneoplastic Evaluation, Serum

-DYS2 / Dysautonomia, Autoimmune/Paraneoplastic Evaluation, Serum

-GID2 / Gastrointestinal Dysmotility, Autoimmune/Paraneoplastic Evaluation, Serum

-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum

 

<1:240

Day(s) Performed

Monday through Sunday

Report Available

5 to 10 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86256